Common questions about Microgynon CD (FAQ)
Q: How quickly does Microgynon CD start working to prevent pregnancy?
A: If you begin taking Microgynon CD on the first day of your menstrual cycle, contraceptive protection is generally considered established immediately. However, if the start is between days 2 and 5 of the cycle, official information indicates that an additional non-hormonal barrier method is advised for the first 7 days of the first cycle.
Q: What are the non-contraceptive uses for Microgynon CD?
A: The sole official indication (approved use) for Microgynon CD is for the prevention of pregnancy (contraception). While studies have examined the pill's effects on menstrual cycle characteristics and pain, these are not considered official indications or uses.
Q: What is the difference between Microgynon CD and Microgynon 30?
A: Microgynon CD is generally recognized as a 28-day pack designed for continuous dosing, containing 21 active hormone tablets followed by 7 hormone-free (placebo) tablets. In contrast, Microgynon 30 is typically a 21-day active pack that requires the user to take a 7-day tablet-free break.
Q: Do all combined oral contraceptives contain the same ingredients as Microgynon CD?
A: No. Microgynon CD contains the fixed-dose combination of levonorgestrel and ethinyl estradiol. The broad pharmacological class of combined oral contraceptives (COCs) includes many different formulations that utilize various types and dosages of synthetic estrogen and progestin hormones.
Q: Can Microgynon CD affect my mood or cause mood swings?
A: Official safety documents list mood changes, including feelings of depression or a depressed mood, as a potential side effect. Users experiencing concerning mood changes are advised to inform a healthcare provider.
Q: Is it normal to experience spotting or breakthrough bleeding when starting Microgynon CD?
A: Yes, spotting or breakthrough bleeding is listed in official documents as a Very Common side effect, meaning it is classified as a Very Common side effect. Irregular bleeding is often noted to be more frequent during the first few cycles of use while the body adjusts to the hormones.
Q: Are there any long-term effects associated with taking Microgynon CD for many years?
A: Regulatory information indicates that certain very rare but serious risks, such as developing some types of hepatic neoplasms (liver tumors), are generally associated with prolonged use. The overall risk of serious vascular events, like blood clots, is primarily observed during the first year of use or upon restarting the medication.
Q: Is it true that the risk of blood clots is highest during the first year of Microgynon CD use?
A: Official patient information states that the risk of developing a venous thromboembolism (VTE) is highest during the first year a woman begins using any combined hormonal contraceptive. This increased risk is also observed when a user restarts the medicine after a break of 4 or more weeks.
Q: Are there any antibiotics that can reduce the effectiveness of Microgynon CD?
A: Yes. Official interaction information specifically names the antibiotics Rifampicin and Griseofulvin as drugs that can reduce the pill’s effectiveness because they are hepatic enzyme inducers. The potential for other prescribed medications to have this enzyme-inducing property is noted in official information.
Q: Does taking Microgynon CD with food or alcohol affect how it works?
A: Official guidance states that taking the tablet is independent of food, meaning it can be consumed with or without a meal. However, regulatory documents do not provide specific safety information or warnings regarding the effects of alcohol on the drug's effectiveness.
Q: Is protection from pregnancy maintained during the hormone-free interval of the Microgynon CD pack?
A: Contraceptive protection is maintained during the 7-day hormone-free interval, provided the active tablets preceding the break were taken correctly and the next pack is started on time. Protection can be compromised if an active tablet is missed or if the hormone-free interval is extended beyond 7 days.
Q: Can Microgynon CD cause changes in my menstrual cycle regularity after I stop taking it?
A: Official patient guidance notes that, after discontinuation, it can take some time for the body to return to its natural hormone production and ovulatory cycle. For some women, the natural menstrual cycle may take a few months to fully return to their individual normal pattern.
Q: Does Microgynon CD offer any protection against sexually transmitted infections (STIs)?
A: No. The official labeling of Microgynon CD clearly states that combined oral contraceptives do not protect against sexually transmitted infections (STIs), including HIV/AIDS. Protection against STIs generally requires the use of barrier methods.
Q: Is the 'period' I get while on Microgynon CD a real menstrual period?
A: The bleeding that occurs during the hormone-free interval of the pill pack is referred to in regulatory documents as a withdrawal bleed, not a true menstrual period. This bleeding is caused by the drop in hormone levels when the user switches from active pills to inactive (placebo) pills.
Q: Can I use Microgynon CD to intentionally delay or skip my withdrawal bleed?
A: Official administration guidance provides instructions for delaying menstruation by skipping the inactive tablet interval and immediately starting a new pack of active tablets. It is noted that breakthrough bleeding or spotting may occur during this extended period of use.
Q: What should I know about switching from a different birth control pill to Microgynon CD?
A: If switching from a 21-day combined pill, Microgynon CD should be started the day after taking the last active tablet of the previous pill. If switching from a progestogen-only pill, a non-hormonal barrier method must generally be used for the first 7 days of taking Microgynon CD.
Q: Are there any common health supplements or herbal products that interact with Microgynon CD?
A: The official interaction list specifically identifies the herbal remedy St John's wort (Hypericum perforatum) as one that can reduce the contraceptive effectiveness of Microgynon CD. The effect of other common supplements is generally a topic of discussion in a patient’s health review.
Q: Can Microgynon CD affect blood test results?
A: Yes, official patient information advises that combined oral contraceptives can interfere with the results of some laboratory tests. Official guidance notes that the patient should inform their doctor or laboratory staff that they are taking the pill before having blood tests performed.
Q: Does Microgynon CD affect fertility after discontinuing its use?
A: The medicine is classified as a reversible method of contraception. Official information indicates that after stopping the pill, fertility will typically return to the individual's normal pattern, although this process may take some time.
Q: Can Microgynon CD cause changes in hair growth or skin condition like acne?
A: Official safety documents list potential skin and hair-related side effects, including both an increase in hair growth and hair loss. Acne is also listed as an adverse reaction that may be associated with use.
Q: Does Microgynon CD contain lactose or other ingredients I should be aware of for allergies?
A: Yes, regulatory documents confirm that Microgynon CD contains lactose as an inactive ingredient. Patients with known intolerances to certain sugars, such as those with rare hereditary problems of galactose intolerance, should consider this information.
Q: What level of efficacy is generally associated with Microgynon CD when taken as directed?
A: When taken strictly and correctly, combined oral contraceptives have a general failure rate of approximately 1% per year. This measure, often quantified by the Pearl Index, increases when tablets are missed or taken inconsistently.
Q: Can taking Microgynon CD impact my vision or comfort with contact lenses?
A: Contact lens intolerance—a feeling of discomfort or difficulty wearing them—is listed as an Uncommon adverse reaction associated with use. This side effect may affect between 1 in 100 and 1 in 1,000 users.
Q: Are there any differences in the use conditions for Microgynon CD after childbirth or breastfeeding?
A: Official guidance states that Microgynon CD is generally not recommended during breastfeeding as it may impact the quantity and composition of breast milk. Specific instructions are provided for starting use 21 days after childbirth if the patient is non-lactating.
Q: Are there different formulations or dosages of Microgynon (like 20 ED or 30) and what do the letters stand for?
A: Yes, Microgynon is available in different formulations. The 30 or 20 in the name typically refers to the dose of the estrogen component (ethinyl estradiol) in micrograms. The CD or ED (Every Day) designation indicates a 28-day regimen that includes 7 inactive tablets.
Q: Is Microgynon CD considered a low-dose combined oral contraceptive?
A: Yes. Microgynon CD contains 30, mu g of ethinyl estradiol, and formulations containing leq 35, mu g of the estrogen component are generally classified in medical literature as a low-dose combined oral contraceptive.
Q: How does Microgynon CD affect the likelihood of getting certain types of cancer? (Other than liver)
A: The official safety profile discusses documented associations with an increased relative risk of breast cancer and cervical cancer. Conversely, some studies cited in regulatory documents suggest that long-term use may be associated with a reduced risk of ovarian and endometrial cancers.
Q: Do I need to take extra precautions if I have a family history of blood clots or cancer?
A: Yes. Official patient information advises that if a close relative has, or has ever had, breast cancer or a history of blood-clotting disorders (thrombophilias), a doctor should be informed, as these factors may require special care or further investigation.
Q: What are the general themes of the research evidence regarding Microgynon CD’s long-term use?
A: Research themes noted in regulatory documents include the measurement of efficacy using the Pearl Index and the study of impacts on menstrual cycle characteristics and menstrual pain (dysmenorrhea). Official sources also note that long-term effects for some outcomes are not fully established due to study length limitations.
